Af­ter se­ri­ous side ef­fect, Sarep­ta and FDA re­align on next-gen Duchenne drug with tri­al hold lift­ed

FDA’s month­s­long tri­al hold on Sarep­ta Ther­a­peu­tics’ next-gen Duchenne mus­cu­lar dy­s­tro­phy drug is out the door af­ter the biotech and reg­u­la­tor hashed out a new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER